Currency In USD
| Previous Close | 24.6 |
| Open | 24.72 |
| Day High | 26.2 |
| Day Low | 24.55 |
| 52-Week High | 38.26 |
| 52-Week Low | 20.23 |
| Volume | 695,751.65 |
| Average Volume | 1.91M |
| Market Cap | 2.69B |
| PE | -7.96 |
| EPS | -3.29 |
| Moving Average 50 Days | 26.53 |
| Moving Average 200 Days | 28.45 |
| Change | 1.58 |
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
GlobeNewswire Inc.
Feb 24, 2026 12:01 PM GMT
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
GlobeNewswire Inc.
Feb 23, 2026 9:00 PM GMT
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and fu